Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tayu Huaxia Biotech Medical Group Co., Ltd.
Beijing, Beijing Shi, Chinapitchbook.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Tayu Huaxia Biotech Medical Group is a clinical-stage biotech company focused on first-in-class immunotherapies. Its lead asset, TY101, is in Phase 1/2 trials for advanced/metastatic solid tumors and relapsed/refractory lymphomas. The trial evaluates safety, tolerability, pharmacokinetics, effectiveness, and immunogenicity of TY101 as a single agent; results have not yet been published as the study remains ongoing[1][3].
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small molecule drugsMonoclonal antibodiesBispecific antibodiesBiological products[1][5]
- Industry
- Biotech
Beyond the preview
Go deeper on Tayu Huaxia Biotech Medical Group Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tayu Huaxia Biotech Medical Group Co., Ltd..